Innovating for Patients
Fueled by a deep scientific expertise built over decades of research, Prothena is integrating scientific insights around protein dysregulation to advance a pipeline of therapeutic candidates for a number of rare peripheral amyloid and neurodegenerative diseases.
Prothena’s wholly owned programs include birtamimab for the potential treatment of AL amyloidosis and a portfolio of programs for the potential treatment of Alzheimer’s disease including PRX012 that targets Aβ (amyloid beta) and the company’s dual Aβ-tau vaccine.
Prothena’s collaborations include prasinezumab, which targets alpha-synuclein, with Roche for the potential treatment of Parkinson’s disease, PRX004 for the potential treatment of ATTR amyloidosis with Novo Nordisk, and programs that target tau (PRX005), TDP-43 and an undisclosed target with Bristol-Myers Squibb for the potential treatment of neurodegenerative diseases.
Kappa & Lambda Light Chain
60,000 – 120,000
Mayo Stage IV
patients globally
α-Synuclein (C-terminus)
10 MILLION
patients globally
Transthyretin (misTTR)
130k – 490k
NYHA Class III and IV Patients Globally
Tau (MTBR)
50 MILLION
patients globally
50% of patients
with Down syndrome
60 years or older
Morie A. Gertz, Heather J. Landau, Brendan M. Weiss
American Journal of Hematology; DOI: 10.1002/ajh.24563; 21 October 2016
Mark Renz, Ronald Torres, Philip J. Dolan, Stephen J. Tam, Jose R. Tapia, Lauri Li, Joshua R. Salmans, Robin M. Barbour, Paul J. Shughrue, Tarlochan Nijjar, Dale Schenk, Gene G. Kinney, Wagner Zago
Amyloid; DOI: 10.1080/13506129.2016.1205974; 2016
Morie A. Gertz, Heather Landau, Raymond L. Comenzo, David Seldin, Brendan Weiss, Jeffrey Zonder, Giampaolo Merlini, Stefan Schönland, Jackie Walling, G.G. Kinney, Martin Koller, Dale B. Schenk, Spencer D. Guthrie, Michaela Liedtke
Journal of Clinical Oncology; DOI:10.1200/JCO.2015.63.6530; 8 February 2016
AL Amyloid Imaging and Therapy with a Monoclonal Antibody to a Cryptic Epitope on Amyloid Fibrils
J.S. Wall, S.J. Kennel, A. Williams, T. Richey, A. Stuckey, Y. Huang, S. Macy, R. Donnell, R. Barbour, P. Seubert, D. Schenk
PLoS ONE; 7(12):e52686; 2012
Generation and Characterization of anti-AA Amyloid-Specific Monoclonal Antibodies
J.S. Wall, S.J. Kennel, T. Richey, A. Allen, A. Stuckey, D.T. Weiss, R. Barbour, P. Seubert, A. Solomon, D. Schenk
Frontiers of Immunology; DOI:10.3389/fimmu.2011.00032; 2011
Work Outcomes Among Patients with Light Chain Amyloidosis: Findings from Three Patient Cohorts
Avery A. Rizio, Kristen L. McCausland, Michelle K. White, Tiffany P. Quock
Patient Related Outcome Measures; DOI:10.2147/PROM.S337676; 2021
Quock TP, Yan JT, Tieu R, D’Souza A, Broder MS
ClinicoEconomics and Outcomes Research; (11) 431-439; 2019
McCausland KL, Rizio AA, White MK, Bayliss MS, Quock TP
PharmacoEconomics; 1-9; 22 February 2019
Cardiac biomarkers and health-related quality of life in patients with light chain (AL) amyloidosis
McCausland KL, Quock TP, Rizio AA, Bayliss MS, White MK, Guthrie SD, Sanchorawala V
British Journal of Haematology; 22 November 2018
Treatment Tolerability in Patients with Light Chain Amyloidosis
Rizio AA, White MK, McCausland KL, Quock TP, Guthrie SD, Yokota M, Bayliss MS
American Health and Drug Benefits; 11(8); 2018
Mortality and Healthcare Costs in Medicare Beneficiaries with AL Amyloidosis
Quock TP, Chang E, Munday JS, D’Souza A, Gokhale S, Yan JT
Journal of Comparative Effectiveness; 7(11); 25 October 2018
Epidemiology of AL Amyloidosis: A Real-World Study Using US Claims Data
Quock TP, Yan JT, Chang E, Guthrie S, Broder MS
Blood Advances; 2(10): 1046-1053; 2018
Quock TP, Yan JT, Chang E, Guthrie S, Broder MS
Journal of Comparative Effectiveness Research; DOI: 10.2217/cer-2017-0100; 2 February 2018
Light Chain (AL) Amyloidosis: The Journey to Diagnosis
McCausland KL, White MK, Guthrie SD, Quock TP, Finkel M, Lousada I, Bayliss MS
Patient 2017; DOI: 10.1007/s40271-017-0273-5; 4 August 2017
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease A Randomized Clinical Trial
Joseph Jankovic, MD; Ira Goodman, MD; Beth Safirstein, MD; Tonya K. Marmon, DrPH; Dale B. Schenk, PhD; Martin Koller,MD, MPH;Wagner Zago, PhD; Daniel K. Ness, DVM, PhD; Sue G. Griffith, MD, PhD, MRCP; Michael Grundman, MD, MPH; Jay Soto, BS; Susanne Ostrowitzki, MD, PhD; Frank G. Boess, PhD; Meret Martin-Facklam, PhD; Joseph F. Quinn, MD; Stuart H. Isaacson, MD; Omid Omidvar, MD; Aaron Ellenbogen, DO; Gene G. Kinney, PhD
JAMA Neurology; DOI: 10.1001/jamaneurol.2018.1487, Published online June 18, 2018.
First-in-human assessment of PRX002, an anti–α-synuclein monoclonal antibody, in healthy volunteers
Dale B. Schenk, Martin Koller, Daniel K. Ness, Sue G. Griffith, Michael Grundman, Wagner Zago, Jay Soto, George Atiee, Susanne Ostrowitzki, and Gene G. Kinney
Movement Disorders, DOI: 10.1002/mds.26878 (2016)
Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson’s Disease-Like Models
D. Games, E. Valera, B. Spencer, E. Rockenstein, M. Mante, A. Adame, C. Patrick, K. Ubhi, S. Nuber, P. Sacayon, W. Zago, P. Seubert, R. Barbour, D. Schenk, and E. Masliah
The Journal of Neuroscience, July 9, 2014 · 34(28):9441-9454 · 9441
Axonopathy in an a-Synuclein Transgenic Model of Lewy Body Disease Is Associated with Extensive Accumulation of C-Terminal-Truncated a-Synuclein
D. Games, P. Seubert, E. Rockenstein, C. Patrick, M.Trejo, K. Ubhi, B. Ettle, M. Ghassemiam, R. Barbour, D. Schenk, S. Nuber, E. Masliah
The American Journal of Pathology, Vol. 182, No. 3, March 2013
Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
E. Masliah, E. Rockenstein, M. Mante, L. Crews, B. Spencer, A. Adame, C. Patrick, M. Trejo, K. Ubhi, T. Rohn, S. Mueller-Steiner, P. Seubert, R. Barbour, L. McConlogue, M. Buttini, D. Games, D. Schenk
PLoS ONE 6 (4), 1-17 (2011)
Novel Conformation-specific Monoclonal Antibodies Against Amyloidogenic Forms of Transthyretin
Jeffrey N. Higaki, Avi Chakrabartty, Natalie J. Galant, Kevin C. Hadley, Bradley Hammerson, Tarlochan Nijjar, Ronald Torres, Jose R. Tapia, Joshua Salmans, Robin Barbour, Stephen J. Tam, Ken Flanagan, Wagner Zago & G. G. Kinney
Amyloid, DOI:10.3109/13506129.2016.1148025 (2016)
Vascular alterations in PDAPP mice following anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities (ARIA)W. Zago, S. Schroeter, T. Guido, K. Khan, P. Seubert, T. Yednock, D. Schenk, K.M. Gregg, D. Games, F. Bard, G.G. Kinney
Alzheimers Dementia 9, S105–S115 (2013)
Neutralization of soluble synaptotoxic Aß species by antibodies is epitope specificW. Zago, M. Buttini, T.A. Comery, C. Nishioka, P. Seubert, D. Games, F. Bard, D. Schenk, G.G. Kinney
Journal of Neuroscience, 32:2696-2702 (2012)
Sustained levels of antibodies against Aß in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic miceF. Bard, M. Fox, S. Friedrich, P. Seubert, D. Schenk, G.G. Kinney, T. Yednock
Exp Neurol., 238:38-43 (2012)
Structural Correlates of Antibodies Associated with Acute Reversal of Amyloid β-related Behavioral Deficits in a Mouse Model of Alzheimer DiseaseG. Basi, H. Feinberg, F. Oshidari, J. Anderson, R. Barbour, J. Baker, T.A. Comery, L. Diep, D. Gill, K. Johnson-Wood, A. Goel, K. Grantcharova, M. Lee, J. Li, A. Partridge, I. Griswold-Prenner, N. Piot, D. Walker, A. Widom, M.N. Pangalos, P. Seubert, J.S. Jacobsen, D. Schenk, W.I. Weis
Journal of Biological Chemistry 285(5):3417-3427 (2010)
Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s DiseaseE. Masliah, E. Rockenstein, A. Adame, M. Alford, L. Crews, M. Hashimoto, P. Seubert, M. Lee, J. Goldstein, T. Chilcote, D. Games, D. Schenk
Neuron 46, 857-868 (2005)
Aβ42 Immunization in Alzheimer’s Disease Generates Aβ N-Terminal AntibodiesM. Lee, F. Bard, K. Johnson-Wood, C. Lee, K. Hu, S. Griffith, R. Black, D. Schenk, P. Seubert
Ann. Neurol. 58, 430-435 (2005)
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouseD. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, Z. Liao, I. Lieberburg, R. Motter, L. Mutter, F. Soriano, G. Shopp, N. Vazquez, C. Vendevert, S. Walker, M. Wogulis, T. Yednock, D. Games, P. Seubert
Nature, 400, 173-177 (1999)
Prothena Corporation plc
2022© Prothena | Terms of Use | Privacy Policy
